Drug Discovery World

FEBRUARY 23, 2024

Sphere Fluidics has welcomed Dr Graeme Daniels as its new Vice President of Sales and Marketing, bringing over 20 years of experience in the life sciences and biotechnology industries. CN Bio has added Joseph Parisi as US Director of Sales. Dr Daniel Turner is the new Chief Scientific Officer at Enhanc3D Genomics.

Drugs 59

Drugs Life Science Sales Genome 59

Pharmaceutical Technology

DECEMBER 14, 2022

The alliance will merge the PRISM oligonucleotide platform of Wave and the capabilities of GSK in genetics and genomics. Additionally, for WVE-006, GSK will make development and launch milestone payments of up to $225m to Wave, which is also eligible to get up to $300m in milestone payments based on sales.

Life Science 162

Life Science Development Gene Therapy Genetics 162

Pharmaceutical Technology

AUGUST 16, 2022

Enhertu has already achieved regulatory approval as a second-line therapy for metastatic or recurrent HER2-positive breast cancer, as well as HER2-positive gastric or gastroesophageal junction adenocarcinoma, with annual sales for these indications alone expected to exceed $1.3bn by 2028.

Sales 147

Sales Trials FDA Approval Development 147

BioTech 365

JANUARY 9, 2022

NanoString Announces Commercial Leadership Transition NanoString Announces Commercial Leadership Transition Chad Brown to Retire Following More than Four Successful Years as SVP, Sales & Marketing Genomics and Diagnostics Veteran John D.

Genome 52

Genome Genomics Sales Marketing 52

Drug Discovery World

MARCH 27, 2023

Macomics will receive an up-front payment, R&D funding, and success-based milestone payments, as well as tiered royalties based on global net sales. Macrophages (TAMs) are often the most abundant immune cell and modulating TAMs can enhance the body’s ability to fight cancer.

Drugs 52

Drugs Antibody Genome Genomics 52

BioSpace

OCTOBER 18, 2022

Editas is reportedly in "advanced discussions" regarding the sale of its preclinical cancer lineup. The company told BioSpace it has undertaken a strategic review to inform opportunities.

Sales 40

Sales Genome Genomics Medicine 40

Pharma Marketing Network

JANUARY 18, 2023

He also has deep experience leading B2B marketing functions for high-growth SaaS and data providers across product marketing, demand creation, sales enablement, and other disciplines. He also attended Singularity University and has an ongoing interest in exponential technologies, including AI, genomics, and nanotech.

Life Science 52

Life Science Marketing Genome Genomics 52

The Pharma Data

DECEMBER 28, 2020

Eurofins Genomics launched an optimized next-generation sequencing service providing full-length viral genome sequences for COVID-19. Whole genome SARS-CoV-2 sequencing identifies mutant strains and spots emerging risks, including potentially immune and vaccine evasive variants, at an early stage.

Genome 52

Genome Genomics Vaccination Vaccine 52

Drug Discovery World

MARCH 7, 2023

Indeed, QCRI is currently working with other organisations in Qatar including Qatar Biobank, to further research and develop data sets that contain whole genome sequences. “Current work at QCRI focuses on developing polygenic risk scores for complex diseases and traits using local Qatari data.

Biobanking 52

Biobanking Drugs Genome Genomics 52

Pharmaceutical Technology

JANUARY 20, 2023

billion in Covid-19 vaccine sales. In a January business update , the company predicted it will make a minimum of $5 billion in new vaccine sales. On January 4, the company announced plans to acquire Japanese biotech OriCiro Genomics in an $85 million deal. In 2021, Moderna had a net income of $12.2

Manufacturing 246

Manufacturing Vaccination Vaccine Gene Therapy 246

Drug Discovery World

SEPTEMBER 14, 2023

Excluding Covid-19 medicines, total revenue increased 16% and product sales increased 15%. For Sanofi, second quarter 2023 sales growth of 3.3% AstraZeneca saw total revenue reach $22,295m, up 4% despite a decline of $2,181m from Covid-19 medicines. at CER and business EPS growth of 8.1% Specialty care grew 11.8% Vaccines were up 9.1%

Drugs 59

Drugs Vaccination Vaccine Medicine 59

The Pharma Data

JANUARY 12, 2021

Dark Antigens are in reference to a newer class of cancer antigens derived from a portion of the human genome not normally expressed as a protein. This portion of the genome is dubbed the “genomic dark matter.” Additional royalties on future product sales will also be directed toward Enara. “We

Research 52

Research Genome Genomics Licensing 52

pharmaphorum

JANUARY 12, 2021

Dark Antigens represent a new class of cancer-associated antigens that derive from the genomic “dark matter” – the portion of the human genome that is normally not expressed as protein. These sequences are usually silenced in healthy cells but are activated and presented on tumour cells.

Genome 59

Genome Genomics Licensing Licensing 59

The Pharma Data

JANUARY 12, 2021

KSQ is also eligible to receive tiered royalties on net sales of each approved product. sales for that product. KSQ’s proprietary CRISPRomics® discovery engine enables genome-scale, in vivo validated, unbiased drug discovery across broad therapeutic areas. and retain royalties on all ex-U.S.

Development 52

Development Research In-Vivo Genome 52

Pharmaceutical Technology

JULY 29, 2022

A nitrogen-binding drug, its global sales were $292m in 2021, as per GlobalData. According to Bumcrot, regRNAs are “RNAs that arise out of the non-coding genome”. Other treatments include sodium phenylbutyrate marketed as Buphenyl or Ammonaps. GlobalData is the parent company of Pharmaceutical Technology.

RNA 245

RNA Gene Expression Gene Gene Therapy 245

pharmaphorum

JANUARY 24, 2022

The sale also marks a retreat from healthcare for the tech giant, which is remarkable given that it once said it viewed health as second only to financial services market as a market opportunity.

Radiology 110

Radiology Marketing Genome Genomics 110

pharmaphorum

DECEMBER 22, 2020

million on the table if certain development, regulatory and sales goals are achieved. Surface could receive up to $730 million in future milestone payments as well as tiered royalties on global net sales. This deal involves an upfront payment of $7 million but there is up to $154.5

Licensing 52

Licensing Licensing Genetics Sales 52

The Pharma Data

JANUARY 14, 2021

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Containment 52

Containment Genome Genomics Sales 52

Pharmaceutical Technology

DECEMBER 9, 2022

In regards to the latter, notable examples include the acquisition of Cergentis, a genomics-focused biotechnology company based in the Netherlands. The deal allows the company to provide proprietary technology and knowledge steeped in fast-evolving genomic techniques that support effective decision-making and R&D program design.

Development 130

Development Production Manufacturing Vaccination 130

XTalks

DECEMBER 11, 2023

This has culminated in the establishment of a comprehensive sales network, through which the company delivers an extensive array of distinct electrophysiology products. This remarkable upswing can be attributed primarily to amplified sales of TearCare SmartLids and SmartHubs, extending their reach to both new and established customers.

Production 110

Production Sales In-Vitro Development 110

Drug Discovery World

APRIL 8, 2024

Aviv Regev, Head and Executive Vice President of Research and Early Development at Genentech, opened the session with a discussion of how advances in genomic sequencing are fostering the development of data-rich cell atlases and what that data could mean for new insights into cancer biology and novel therapeutics.

In-Vivo 52

In-Vivo In-Vitro Antibody Protein 52

Pharmaceutical Technology

MAY 15, 2023

BMS is a specialty biopharmaceutical company that is engaged in the discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on oncology, cardiovascular, immunology, and fibrotic therapeutic projects.

Antibody 130

Antibody DNA Genome Genomics 130

Camargo

NOVEMBER 11, 2020

Presumably, Antares’ long-established 90-person urology sales force can achieve pull-thru of this drug product. In November 2017, Foundation Medicine received approval for FoundationOne CDx , a genomic profiling test for solid state tumors, which paved the way for partnerships with pharma companies’ therapeutics.

Development 242

Development Bioequivalency Generic Drugs Production 242

pharmaphorum

OCTOBER 1, 2021

It has made Oxford Nanopore’s chief executive and cofounder Gordon Sanghera an on-paper fortune of £63 million, while another cofounder – chief business development officer Spike Willcocks – is now worth £30 million. Chief technology officer Clive Brown is also sitting on a £10 million stake.

Marketing 52

Marketing Business Development Genome Genomics 52

The Pharma Data

DECEMBER 14, 2020

engine along with algorithms tuned to predict BBB permeability played an important role in helping determine which CNS cancers and which genomically-defined subtypes of CNS cancer should be prioritized for development. . We leverage advances in machine learning, genomics, and artificial intelligence by using a proprietary A.I.

Drugs 52

Drugs Genome Genomics DNA 52

Pharmaceutical Technology

DECEMBER 22, 2022

The category crosses over with many of our other categories and can include new products, novel product features, new business practices, new marketing and sales strategies and more. The category includes any projects that demonstrate an innovative approach to the market.

Insulin 130

Insulin Production Development Genetics 130

The Pharma Data

DECEMBER 1, 2020

NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , announced today the pricing of an underwritten public offering of 4,794,521 shares of its common stock at a public offering price of $36.50 CAMBRIDGE, Mass., About Intellia Therapeutics.

In-Vivo 40

In-Vivo Containment Genome Genomics 40

The Pharma Data

JANUARY 19, 2021

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Containment 52

Containment Genome Genomics Sales 52

pharmaphorum

MARCH 12, 2021

One estimate [1] suggests that by 2025 more than 60 million patients will have their genome sequenced. But for life sciences in particular, an industry historically heavily reliant on face-to-face sales interactions, the change has been revolutionary. And those volumes will only increase.

Life Science 109

Life Science Regulation Genome Genomics 109

XTalks

DECEMBER 13, 2023

In 2023, Moderna is poised to achieve sales figures ranging from $6 billion to $8 billion, contingent on the prevailing COVID-19 vaccination rates in the US. The impressive safety and tolerability profile suggest its potential suitability for use in combination with various anti-cancer drugs or as a maintenance therapy.

Genetics 111

Genetics Vaccination Vaccine DNA 111

The Pharma Data

DECEMBER 2, 2020

The issuance and sale of the notes are scheduled to settle on December 7, 2020, subject to customary closing conditions. The issuance and sale of the common stock are scheduled to settle on December 7, 2020, subject to customary closing conditions. (NASDAQ: PROG) today announced the pricing of its offering of $75.0 About Progenity.

Sales 40

Sales In-Vitro Containment Development 40

XTalks

DECEMBER 4, 2023

The vectors can potentially cause cancer by inserting genetic material into a patient’s genome, particularly near cancer-related DNA sequences or suppressors​​​​. billion in sales in the first three quarters of 2023. percent reduction of the risk of disease progression compared to standard of care in large B-cell lymphoma.

Gene Therapy 69

Gene Therapy Gene Clinical Trials Clinical Trials 69

pharmaphorum

FEBRUARY 10, 2022

In recent years, concepts including AI-led candidate selection, centralised clinical data monitoring, online sales, and virtual consultations have moved into primetime, all with the promise of making workflows more efficient. We know that digital transformation has the potential to rewrite the boundaries of the possible in medicine.

Life Science 101

Life Science Genome Genomics Research 101

pharmaphorum

SEPTEMBER 18, 2020

AstraZeneca also wanted to endure shareholder value through global power and reach in sales and marketing, greater financial strategic flexibility and the creation of a stronger R&D platform for innovation-led growth. The merger of Astra and Zeneca aimed to improve the combined companies’ ability to deliver long term growth.

Pharma Companies 115

Pharma Companies Sales Vaccination Vaccine 115

The Pharma Data

NOVEMBER 14, 2021

In recent years, the company has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights. billion in R&D and posted sales of CHF 58.3 In 2020, Roche invested CHF 12.2 Genentech, in the United States, is a wholly owned member of the Roche Group.

In-Vitro 52

In-Vitro Medicine Genome Genomics 52

The Pharma Data

JANUARY 20, 2021

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

Sales 40

Sales Genome Genomics Medicine 40

pharmaphorum

APRIL 14, 2021

The drug has gone on to become a huge success, generating sales of nearly $1.8 These cancer cells have switched to this backup system to repair DNA damage and by turning it off, PARP inhibitors cause them to die from a process known as “synthetic lethality” as mutations in their genome run out of control.

Drugs 58

Drugs DNA Genome Genomics 58